Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (19983)	3/22/1999 6:41:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

martin, The bottom line is that the only way Vivus will substantially recover is by showing some decent earnings and increased product sales. We already know that the international product sales picture will soon be changing for the better. We also know that domestic sales can increase back to respectable levels if and when Vivus can finally sign a marketing partner. The female SD patent is a new reason for institutions to accumulate Vivus stock. I don't think this type of product is mere hype and can eventually pull in much better profits for Vivus than we ever saw from MUSE. A female SD product may be used by Vivus as another bargaining chip involving a domestic partner. I think that currently the Street is fixated on the domestic marketing partner and we should see one within the next 1 to 3 months.